Status:

COMPLETED

Comparison of Pharmacokinetics of Dipyridamole in Asasantin Extended Release (ER) and in a Combination of Persantin Immediate Release Tablets and ASA Tablets in Healthy Subjects

Lead Sponsor:

Boehringer Ingelheim

Conditions:

Healthy

Eligibility:

All Genders

18-55 years

Phase:

PHASE1

Brief Summary

Comparative Pharmacokinetics of Asasantin Extended Release (ER) and of immediate release Persantin tablets combined with Acetyl salicylic acid (ASA) tablets

Eligibility Criteria

Inclusion

  • Healthy subjects as determined by results of screening
  • Signed informed consent in accordance with Good Clinical Practice (GCP) and local legislation
  • Age \>= 18 and \<= 55 years
  • Broca \>= - 20% and \<= + 20%

Exclusion

  • Any findings of the medical examination (including blood pressure, pulse rate and ECG) deviating from normal and of clinical relevance
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorder
  • Surgery of the gastro-intestinal tract (except appendectomy)
  • Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
  • Chronic or relevant acute infections
  • History or hypersensitivity to Asasantin ER and any of the excipients
  • Intake of drugs with a long half-life (\> 24 hours) (\<= 1 month prior to administration or during the trial)
  • Use of any drugs which might influence the result of the trial (\<= 10 days prior to administration or during the trial)
  • Participation in another trial with an investigational drug (\<= 1 month prior to administration or during the trial)
  • Known alcohol abuse
  • Known drug abuse
  • Blood donation ( \<=1 month prior to administration or during the trial)
  • Excessive physical activities (\<=5 days prior to administration or during the trial)
  • History of hemorrhagic diseases
  • History of gastro-intestinal ulcer, perforation or bleeding
  • History of bronchial asthma
  • Any laboratory value outside the reference range of clinical relevance
  • For female subjects:
  • Pregnancy
  • Positive pregnant test
  • No adequate contraception (adequate contraception e.g. sterilization, intrauterine device (IUD), oral contraceptives)
  • Inability to maintain this adequate contraception during the whole study period
  • Lactation period

Key Trial Info

Start Date :

April 1 2000

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

Estimated Enrollment :

20 Patients enrolled

Trial Details

Trial ID

NCT02273505

Start Date

April 1 2000

Last Update

October 24 2014

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

Comparison of Pharmacokinetics of Dipyridamole in Asasantin Extended Release (ER) and in a Combination of Persantin Immediate Release Tablets and ASA Tablets in Healthy Subjects | DecenTrialz